The faculty open the Between the Lines discussion by framing why advanced biliary tract cancer (BTC) remains a difficult-to-treat malignancy with rising incidence.
The discussion turns to the TOPAZ-1 study design and its long-term efficacy update.
The faculty review patient-reported outcomes, subgroup consistency, and biomarker testing before introducing the second pivotal trial.
The panel reviews the KEYNOTE-966 long-term follow-up data.
The discussion moves to real-world evidence and meta-analysis.
The faculty step back to compare trial data with real-world evidence before reviewing a phase 3b feasibility study.
The faculty synthesize the evidence into clinical positioning and outline the questions that remain open.
In the closing discussion, the faculty address how they choose between the available chemoimmunotherapy regimens and where the field is heading.
